- Home
- OKYO vs ICMB Comparison
OKYO vs ICMB Comparison
Compare OKYO & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- ICMB
- Stock Information
- Founded
- OKYO 2007
- ICMB 2012
- Country
- OKYO United Kingdom
- ICMB United States
- Employees
- OKYO N/A
- ICMB N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- ICMB Finance: Consumer Services
- Sector
- OKYO Health Care
- ICMB Finance
- Exchange
- OKYO Nasdaq
- ICMB Nasdaq
- Market Cap
- OKYO 37.0M
- ICMB 41.1M
- IPO Year
- OKYO 2022
- ICMB N/A
- Fundamental
- Price
- OKYO $2.41
- ICMB $2.75
- Analyst Decision
- OKYO Strong Buy
- ICMB
- Analyst Count
- OKYO 1
- ICMB 0
- Target Price
- OKYO $7.00
- ICMB N/A
- AVG Volume (30 Days)
- OKYO 213.3K
- ICMB 27.9K
- Earning Date
- OKYO 08-12-2025
- ICMB 05-13-2025
- Dividend Yield
- OKYO N/A
- ICMB 16.67%
- EPS Growth
- OKYO N/A
- ICMB N/A
- EPS
- OKYO N/A
- ICMB 0.82
- Revenue
- OKYO N/A
- ICMB $20,996,189.00
- Revenue This Year
- OKYO N/A
- ICMB N/A
- Revenue Next Year
- OKYO N/A
- ICMB N/A
- P/E Ratio
- OKYO N/A
- ICMB $3.49
- Revenue Growth
- OKYO N/A
- ICMB N/A
- 52 Week Low
- OKYO $0.81
- ICMB $2.46
- 52 Week High
- OKYO $3.11
- ICMB $3.47
- Technical
- Relative Strength Index (RSI)
- OKYO 58.01
- ICMB 44.96
- Support Level
- OKYO $2.05
- ICMB $2.73
- Resistance Level
- OKYO $2.49
- ICMB $2.95
- Average True Range (ATR)
- OKYO 0.31
- ICMB 0.11
- MACD
- OKYO -0.01
- ICMB 0.00
- Stochastic Oscillator
- OKYO 44.44
- ICMB 16.67
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.